Preclinical Candidate to Commercial Therapy
The founder's path from preclinical candidate to commercial therapy. IND strategy as a capital structure decision, CDMO selection and its downstream consequences, CMC development milestones as funding triggers, and the manufacturing scale-up gap that destroys biotech companies between Phase II and commercial launch.